{"id":"NCT01071070","sponsor":"Abbott","briefTitle":"Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease","officialTitle":"A Phase 3b, Randomized, Active-Controlled, Single-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Injection in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects Receiving Hemodialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-02-19","resultsPosted":"2012-01-26","lastUpdate":"2012-01-26"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"paricalcitol","otherNames":["ABT-358","Zemplar"]}],"arms":[{"label":"Group 1","type":"ACTIVE_COMPARATOR"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease","primaryOutcome":{"measure":"The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels","timeFrame":"Baseline to 12 Weeks","effectByArm":[{"arm":"Group 1","deltaMin":93,"sd":null},{"arm":"Group 2","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Upper respiratory tract infection","Diarrhoea","Hypertension","Pyrexia","Hypoglycaemia"]}}